Abbott India Share Price Target 2025, 2026, 2030, 2040, 2050
Abbott India is the Indian branch of the global company Abbott Laboratories. It makes and sells many trusted medicines and health products in India. The company produces common branded medicines, nutrition powders, medical test tools, and simple medical devices. It works in many important health areas like women’s health, heart problems, stomach issues, thyroid care, diabetes, mind and nerve health, pain relief, and general health needs. It is one of the fast-growing medicine companies in India, helping people in cities and small towns by giving safe, useful, and easy-to-use healthcare products.
- 1 What is Abbott India Ltd NSE: ABBOTINDIA?
- 2 Abbott India Share Price Target
- 3 Abbott India Share Price Target 2025
- 4 Abbott India Share Price Target 2026
- 5 Share Price Target 2027
- 6 Share Price Target 2028
- 7 Share Price Target 2029
- 8 Abbott India share price Target 2030
- 9 Share Price Target 2040
- 10 Share Price Target 2050
- 11 Should I buy Abbott India stock?
- 12 Abbott India earnings results
- 13 Is Abbott India stock good to buy? (bull case & bear case)
- 14 Conclusion
- 15 FAQs
What is Abbott India Ltd NSE: ABBOTINDIA?
Abbott India was established in 1944 in Mumbai. It is owned by the global healthcare company Abbott Laboratories. It is a well-known healthcare company in India that makes and sells many useful health products like medicines, medical devices, test tools, and nutrition powders for children and adults. The company mainly works in areas like women’s health, stomach care, heart health, diabetes, thyroid problems, and general health. It has good factories in India and a strong supply network, helping it provide safe and trusted healthcare products to people across the country.
It is the Indian branch of the global healthcare company Abbott Laboratories. The company offers medicines, nutrition powders and drinks, medical test tools, and simple health devices that people use in their daily lives. It has been in India for more than 100 years, which shows that people trust it and that it understands Indian health needs very well. Today, it is growing fast and reaching people in cities, towns, and villages. Its main aim is to help people live longer, stronger, and healthier lives with high-quality care. In 2025, its share price target would be ₹37000, as per stock market analysts.
According to stock market analysts, its share price would be between ₹25325 to ₹37000 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 25325 | 37000 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 25325 | 30668 |
| February | 25743 | 30650 |
| March | 29264 | 31898 |
| April | 27500 | 31400 |
| May | 29555 | 31590 |
| June | 30110 | 37000 |
| July | 32565 | 35955 |
| August | 31175 | 34815 |
| September | 29060 | 32775 |
| October | 28900 | 30560 |
| November | 28600 | 30655 |
| December | 26368 | 31853 |
It is owned by Abbott Laboratories, a very large healthcare company from the United States. It works in more than 160 countries and makes health technologies that help people live better lives. Because it is part of this big global company, it gets access to modern science, strong research, and new technology. This helps the company to make safe and high-quality products for Indian people. The parent company gives strong support, knowledge, and global experience. This mix of global strength and local understanding helps Abbott serve millions of families across India. In 2026, its share price target would be ₹46879, as per stock market analysts.
According to stock market analysts, its share price would be between ₹31000 to ₹46879 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 31000 | 46879 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 31000 | 35510 |
| February | 33540 | 37411 |
| March | 34587 | 38250 |
| April | 35410 | 38987 |
| May | 36674 | 39451 |
| June | 36995 | 40841 |
| July | 38415 | 41554 |
| August | 39478 | 41951 |
| September | 40589 | 42558 |
| October | 40841 | 43954 |
| November | 41547 | 44588 |
| December | 42848 | 46879 |
It is well known for its strong range of branded generic medicines. These medicines are trusted by doctors and used every day by millions of patients. The company makes medicines for heart problems, stomach issues, thyroid disorders, diabetes, infections, nerve health, women’s health, and basic wellness. Many of these medicines are used for long-term treatment, so they become part of a person’s daily routine. Doctors choose the company because the company focuses on quality, safety, and reliable results. In 2027, its share price target would be ₹57774, as per stock market analysts.
According to stock market analysts, its share price would be between ₹46110 to ₹57774 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 46110 | 57774 |
It also has a strong nutrition business that makes science-based powders and drinks for different age groups. These products help children grow, help adults stay active, and support older people with strength and immunity. It studied Indian food habits and lifestyles to make nutrition that fits Indian needs. Families, doctors, and hospitals trust these nutrition products because they provide important proteins, vitamins, and minerals. These products help people recover from illness, improve their energy, and stay strong every day. In 2028, its share price target would be ₹67036, as per stock market analysts.
According to stock market analysts, its share price would be between ₹56147 to ₹67036 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 56147 | 67036 |
It also provides advanced diagnostic tools that help doctors find health problems quickly and correctly. These include blood-testing machines, quick test kits, and hospital lab tools. Good testing helps doctors find diseases early, which leads to faster treatment and better recovery. Its diagnostic tools are used to test for heart problems, diabetes, thyroid issues, infections, and many other diseases. It helps people get the right treatment at the right time. The company continues to bring new testing technologies to support modern healthcare in India. In 2029, its share price target would be ₹76490, as per stock market analysts.
According to stock market analysts, its share price would be between ₹66541 to ₹76490 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 66541 | 76490 |
It offers many simple and helpful medical devices that make health monitoring easy. These include devices for checking blood sugar, heart activity, and general health conditions. The devices are made to be easy to use, so people can check their health at home without any trouble. It provides global-quality devices that make life safer and healthier, with technology becoming more important. These tools help people watch their health, avoid serious problems, and make good lifestyle choices. In 2030, its share price target would be ₹84980, as per stock market analysts.
According to stock market analysts, its share price would be between ₹75125 to ₹84980 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 75125 | 84980 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 75125 | 77415 |
| February | 75841 | 77998 |
| March | 76254 | 78551 |
| April | 76854 | 78745 |
| May | 77254 | 79664 |
| June | 77645 | 79841 |
| July | 77841 | 80257 |
| August | 78100 | 80745 |
| September | 78351 | 81257 |
| October | 78528 | 82580 |
| November | 79668 | 83954 |
| December | 81547 | 84980 |
It works in many medical areas, so it can help people with different kinds of health problems. These include women’s health, digestion, heart care, thyroid support, hormone care, diabetes control, nerve and mental health, infections, and overall wellness. Each area needs different treatments, and it creates products that are safe, effective, and easy to use. Doctors trust Abbott because the company focuses on strong science, research, and quality. In 2040, its share price target would be ₹130630, as per stock market analysts.
According to stock market analysts, its share price would be between ₹121542 to ₹130630 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 121542 | 130630 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 121542 | 123451 |
| February | 122124 | 123884 |
| March | 122584 | 123954 |
| April | 122895 | 124587 |
| May | 123554 | 125214 |
| June | 123854 | 125841 |
| July | 124241 | 126674 |
| August | 125574 | 127125 |
| September | 126234 | 127889 |
| October | 126457 | 128644 |
| November | 127841 | 129125 |
| December | 122798 | 130630 |
It has a very strong supply and distribution network that helps its products reach almost every part of the country. The company works with many distributors, pharmacies, and hospitals to make sure its products are easy to find. Whether someone lives in a big city or a small village, it try to ensure its medicines and products are always available. It uses safe storage, good transport, and careful handling to keep products fresh and safe. This strong distribution system is one of its biggest strengths in India. In 2050, its share price target would be ₹177869, as per stock market analysts.
According to stock market analysts, its share price would be between ₹165583 to ₹177869 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 165583 | 177869 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 165583 | 168410 |
| February | 166325 | 169254 |
| March | 167551 | 170547 |
| April | 168235 | 170891 |
| May | 169110 | 171254 |
| June | 169845 | 172687 |
| July | 170124 | 173651 |
| August | 171254 | 174555 |
| September | 172561 | 175951 |
| October | 173668 | 176621 |
| November | 174547 | 177251 |
| December | 175521 | 177869 |
Should I buy Abbott India stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 25325 | 37000 |
| 2026 | 31000 | 46879 |
| 2027 | 46110 | 57774 |
| 2028 | 56147 | 67036 |
| 2029 | 66541 | 76490 |
| 2030 | 75125 | 84980 |
| 2040 | 121542 | 130630 |
| 2050 | 165583 | 177869 |
It could be a good choice for long-term investors who want a safe and steady healthcare company, because it has grown well over the years and offers many trusted products like medicines, nutrition items, testing tools, and medical devices. It also gets strong support from its global parent company, Abbott Laboratories. The stock is generally stable since people always need healthcare, but it can still be affected by things like high pricing, government rules, strong competition, and changes in the market. Overall, it could be suitable for people who want slow, steady growth with lower risk.
Abbott India earnings results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
| Sales + | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,714 |
| Expenses + | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 4,902 |
| Operating Profit | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,812 |
| OPM % | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income + | 114 | 81 | 77 | 154 | 248 | 275 | 291 |
| Interest | 9 | 18 | 19 | 16 | 12 | 11 | 20 |
| Depreciation | 60 | 58 | 66 | 70 | 71 | 72 | 74 |
| Profit before tax | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,009 |
| Tax % | 26% | 25% | 26% | 25% | 26% | 25% | |
| Net Profit + | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,509 |
| EPS in Rs | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 710.12 |
| Dividend Payout % | 90% | 85% | 73% | 73% | 73% | 71% |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 40.76 | 14.53 | 1.64% | 36.87 | 5.82 | 0.59% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| Abbott India Ltd | 43.48 | 14.53 | 1.64% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
Is Abbott India stock good to buy? (bull case & bear case)
Bull Case:
- In FY25, its revenue rose to around ₹6,409 crore, up from ₹5,849 crore in FY24, showing good growth.
- Its net profit for FY25 was ₹1,414 crore, which is about 18% higher than the previous year, showing strong earnings.
- Profit margins improved, with net profit margin reaching around 22%, which shows better cost control and efficiency.
- The company has very little debt and a strong cash position, which makes it financially safe.
- It works in many areas, including medicines, nutrition, diagnostics, and devices, so it is less affected if one area slows down.
- Demand for healthcare products like chronic disease medicines, diagnostics, and nutrition is stable, which keeps sales steady even in difficult times.
Bear Case:
- Rising raw-material costs or higher regulatory costs could reduce profit, which may affect the ~22% net profit margin.
- Government rules, like price controls or stricter regulations on drugs and exports, could reduce growth and earnings.
- Competition from other Indian and international companies could affect Abbott’s market share and pricing.
- Some products, like non-essential medicines or nutrition items, may see less demand during an economic slowdown, which could lower sales.
Conclusion
The company makes and sells trusted medicines, nutrition products, simple medical devices, and test tools for health areas like women’s health, heart care, diabetes, thyroid, and general wellness. It has good factories, a strong supply system, and over 100 years in India, it provides safe and reliable healthcare products to people in both cities and villages. Even though competition and government rules could affect growth, it is a safe and steady choice for long-term investors.
